Pfizer Inc. (PFE)
Will Pfizer's Non-COVID Portfolio Drive Its Next Phase of Growth?
PFE's non-COVID products are gaining momentum, with launches, acquisitions and a pipeline aimed at driving growth from 2029 onward.
Pfizer's Pipeline Could Change Everything
Pfizer is recovering from post-COVID and LOE-driven declines, with recent earnings beats and an attractive valuation supporting upside potential. PFE's Q2 2026 results showed 1% operational revenue growth and a 12% EPS beat, driven by solid non-COVID sales and a robust growth portfolio. Cost Realignment Program expansions are set to deliver $7.2B in net savings by 2026 and another $2.5B through 2029, enhancing future earnings.
Pfizer Rises Almost 7% Post Q2 Results: How to Play the Stock
Pfizer's Q2 beat and raised 2026 revenue outlook signal progress, but declining COVID sales and patent losses challenge its growth path.
Monster insider trading alert for Pfizer stock
As Pfizer Inc. (NYSE: PFE) stock gained over 5% this week fueled by its strong second quarter 2026 earnings report, Finbold has observed its increased insider trading.
After Q2 Earnings, Is Pfizer or Merck the Smarter Dividend Play?
Pfizer (NYSE:PFE | PFE Price Prediction) and Merck (NYSE:MRK) refreshed the dividend debate with their latest quarterly reports.
Pfizer: Q2 Strength Overshadows Obesity Setbacks
Pfizer shares edged higher after Q2 earnings, shrugging off criticism over the discontinuation of two obesity drug candidates, MET-224o and PF-07976016. PFE highlighted Metsera's rapid progress and plans to strategically deploy its remaining $6 billion-$7 billion toward bolt-on opportunities in oncology, IMIDs, and obesity. In Q2, sales of the tafamidis franchise were $1.76 billion, up 10% QoQ.
Pfizer Q2 Earnings Call Highlights Non-COVID Growth and Cost Cuts
PFE raises its 2026 revenue outlook as non-COVID growth, deeper cost cuts and pipeline catalysts offset weaker COVID demand.
Pfizer Q2 Earnings Call Highlights
Pfizer NYSE: PFE reported second-quarter 2026 revenue of $15 billion and adjusted diluted earnings per share of $0.77, with management saying both measures exceeded its internal expectations. Revenue increased 1% operationally from a year earlier, while revenue excluding COVID-19 products rose 5% operationally.
PFE Q2 Earnings Top, 2026 Sales View Tweaked, COVID Forecast Cut
Pfizer beats Q2 earnings and revenue estimates, raises the low end of its 2026 sales outlook, but lowers expectations for COVID product revenues.
Compared to Estimates, Pfizer (PFE) Q2 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for Pfizer (PFE) give a sense of how the business performed in the quarter ended June 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Pfizer raises revenue outlook after quarterly earnings top estimates
Pfizer Inc (NYSE:PFE, XETRA:PFE) beat Wall Street expectations for its second-quarter 2026 results and raised the midpoint of its full-year revenue guidance, as growth from launched and acquired products helped offset declines in its COVID-19 portfolio. The pharmaceutical company reported adjusted earnings of $0.77 per share for the quarter, above the $0.68 expected by analysts.
Pfizer (PFE) Q2 Earnings and Revenues Top Estimates
Pfizer (PFE) came out with quarterly earnings of $0.77 per share, beating the Zacks Consensus Estimate of $0.68 per share. This compares to earnings of $0.78 per share a year ago.
